Finnish biotech Genomill Health introduced Bridge Capture, a novel targeted next-generation sequencing sample preparation technique enabling simple, cost-effective, and automatable detection of genetic mutations critical in cancer profiling and minimal residual disease assessment. The method uses dual-specific probes circularized on the target DNA, compatible with multiple sequencing platforms including nanopore and circular template sequencers. Early pilot studies published in Scientific Reports demonstrate promising performance, positioning Bridge Capture as a competitive alternative for clinical molecular diagnostics workflows.